Here is an excerpt from my 5/19/11 post. Wow, my memory is terrible. I wasn't the OLDEST participant - I was the YOUNGEST!!
"Some of the bottom lines are: With follow up to 85 months (average 31 months) there is a recurrence-free survival rate of 77%. The average recurrence was at 7 months - so if it recurs, it is usually pretty quickly. Once again, this is RALP only.
The study is in the Journal of Endourology, Volume 24, Number 12, December 2010. Title: Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting.
Engel is associated with the George Washington University Hospital in Washington, DC."
I hope you can find it. Let me know if you can't. I have a paper copy somewhere. Maybe I can scan it and post it.
Good luck to you,
I had to copy and paste that link to get it to work.
Since I had one positive margin foci, I love this part: "There was no significant difference in surgical margin positivity (38% overall) or prostate size between recurrence and nonrecurrence cohorts."
Thx again, Kc!
J Endourol. 2010 Dec;24(12):1963-6. doi: 10.1089/end.2010.0305. Epub 2010 Nov 18.
Oncologic outcome of robot-assisted laparoscopic prostatectomy in the high-risk setting.
Engel JD1, Kao WW, Williams SB, Hong YM.
1Department of Urology, George Washington University Hospital, Washington, District of Columbia 20006, USA. email@example.com
BACKGROUND AND PURPOSE:
Previous studies have demonstrated the feasibility of
open radical prostatectomy in the high-risk setting. Management of high-risk disease with robot-assisted laparoscopic radical prostatectomy (RALP) is controversial. We examined biochemical recurrence in a selected cohort of high-risk patients who were undergoing RALP.
PATIENTS AND METHODS:
Men with high-risk prostate cancer who underwent bilateral nerve-sparing, nonsalvage RALP by a single surgeon without adjuvant or neoadjuvant therapy of any kind were identified. High risk was defined by preoperative prostate-specific antigen (PSA) level >10 ng/dL, Gleason score ≥8 on final pathologic evaluation, or stage ≥pT(3). Postoperative PSA value ≥0.2 ng/dL defined biochemical recurrence.
A total of 73 men were identified. There was no significant difference in surgical margin positivity (38% overall) or prostate size between recurrence and nonrecurrence cohorts. Biochemical failure was significantly associated with higher pathologic Gleason score (P = 0.0085) but not pathologic stage (P = 0.22) or preoperative PSA level (P = 0.18). With follow-up to 85 months (mean 31.8 mos), biochemical recurrence-free survival was 77% with mean time to recurrence of 7.7 months. Recurrence occurred significantly earlier than later (P < 0.001).
Reasonable short- to intermediate-term biochemical outcomes can be achieved in a recurrence-prone group of high-risk men who are undergoing RALP. RALP is feasible in a selected cohort of high-risk men who are undergoing aggressive local therapy.
Post Edited (BillyBob@388) : 8/18/2014 8:36:51 PM (GMT-6)